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Abstract
Background: Little is known about acute hemodialysis in the US. Here we describe predictors of receipt of acute
hemodialysis in one state and estimate the marginal impact of acute hemodialysis on survival after accounting for
confounding due to illness severity.
Materials and Methods: This is a retrospective cohort study of acute-care hospitalizations in Pennsylvania from October
2005 to December 2007 using data from the Pennsylvania Health Care Cost Containment Council. Exposure variable is acute
hemodialysis; dependent variable is survival following acute hemodialysis. We used multivariable logistic regression to
determine propensity to receive acute hemodialysis and then, for a Cox proportional hazards model, matched acute
hemodialysis and non-acute hemodialysis patients 1:5 on this propensity.
Results: In 2,131,248 admissions of adults without end-stage renal disease, there were 6,657 instances of acute
hemodialysis. In analyses adjusted for predicted probability of death upon admission plus other covariates and stratified on
age, being male, black, and insured were independent predictors of receipt of acute hemodialysis. One-year post-admission
mortality was 43% for those receiving acute hemodialysis, compared to 13% among those not receiving acute hemodialysis.
After matching on propensity to receive acute hemodialysis and adjusting for predicted probability of death upon
admission, patients who received acute hemodialysis had a higher risk of death than patients who did not over at least 1
year of follow-up (hazard ratio 1?82, 95% confidence interval 1?68–1?97).
Conclusions: In a populous US state, receipt of acute hemodialysis varied by age, sex, race, and insurance status even after
adjustment for illness severity. In a comparison of patients with similar propensity to receive acute hemodialysis, those who
did receive it were less likely to survive than those who did not. These findings raise questions about reasons for lack of
benefit.
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Introduction
Acute hemodialysis (HD), defined as intermittent or continuous,
non-peritoneal renal replacement therapy for patients without
end-stage renal disease (ESRD), typically in the context of critical
illness, is thought to save lives. Overall, however, the prognosis for
patients requiring acute HD is poor, with estimates of in-hospital
mortality in the literature ranging from 33% [1]-61% [2]. In a
large high-quality clinical trial comparing different intensities of
renal support for patients with acute kidney injury (AKI), 60-day
mortality was nearly 53% [3]; in another such trial, 90-day
mortality approached 45% [4]. Moreover, survivors are at high
risk for continued renal failure [5–9] and decreased quality of life
[10–12], and acute HD adds to the already substantial cost of care
for the critically ill in the US [13,14].
Although the US Renal Data System provides detailed
information about patients with ESRD undergoing chronic HD,
less is known about the epidemiology of acute HD. Several studies,
most notably that of Xue and colleagues [1], have reported on the
incidence and mortality of AKI among various populations of
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hospitalized patients in the US [2,6,8]. To our knowledge,
however, no study has specifically focused on the predictors of
or survival after acute HD.
In the current study, we describe predictors of the receipt of
acute HD in a dataset encompassing over 2 million hospital
admissions. We then attempt to estimate the marginal impact of
acute HD on patient survival after accounting for confounding due
to illness severity.
Materials and Methods
Data source
We conducted a retrospective cohort study of adult acute-care
hospitalizations in Pennsylvania from October 2005 to December
2007 using data from the Pennsylvania (PA) Health Care Cost
Containment Council (PHC4) linked to PA Department of Health
death data through December 2008. PHC4 is an independent
state agency that collects this data under mandate from the state
government. The PHC4 data includes patient demographics,
International Classification of Diseases, 9th Revision, Clinical
Modification (ICD-9-CM) diagnosis and procedure codes, and the
predicted probability of inpatient death at the time of admission
for all patients with certain pre-specified diagnosis-related groups
(DRGs) and ICD-9-CM codes. (See Text S1. Diagnosis-related
groups or International Classification of Diseases, 9th Revision,
Clinical Modification principal diagnoses for which the Pennsyl-
vania Health Care Cost Containment Council required predicted
probability of inpatient death to be calculated, by year.) The
predicted probability of death (PPD) is based upon MediQual
mortality models using key clinical findings abstracted from the
chart during the first 48 hours of admission. These models
significantly out-perform those based upon administrative fields
alone, with average c-statistics of 0.86 [15]. It is important to note
that the PHC4 data does not include any Current Procedural
Terminology (CPT) codes; therefore, it is not possible to
distinguish between intermittent HD and all other forms of renal
replacement therapy in the PHC4 data.
Exposure variable
Our principal exposure variable was acute HD. We defined
acute HD as the receipt of HD (ICD-9-CM procedure code 39.95)
by patients without ESRD. We excluded from all analyses
admissions with ICD-9-CM diagnosis codes that would indicate
current ESRD (585.6, V45.1, V45.11, V45.12, V56.xx), imminent
ESRD, i.e., stage 5 chronic kidney disease (CKD) (585.5), or prior
ESRD treated with kidney transplant (V42.0). We further
excluded admissions with ICD-9-CM procedure codes for kidney
transplant (55.6, 55.61, 55.69) or peritoneal dialysis (54.98), as
these are procedures that only patients with ESRD undergo. For a
flowchart depicting the sample selection process, see Figure 1.
Dependent variable
The primary dependent variable is time to death, in days, from
hospital admission. The minimum length of follow-up was one
year.
Covariates
Patient-level covariates included demographics, insurance status
(commercial and/or Medicare, Medicaid with or without Medi-
care, and uninsured), principal diagnoses (classified into groups
from ICD-9-CM codes using Agency for Healthcare Research and
Quality Clinical Classification Software), and illness severity, as
measured by the MediQual PPD (available for the 67% of
admissions with one of the DRGs or ICD-9-CM codes for which
PHC4 required that it be calculated). Hospital-level covariates
included number of hospital beds, resident-to-bed ratio (a measure
of teaching intensity), percent of patients who are black (a measure
of racial concentration, correlated with treatment intensity and
risk-adjusted mortality), and a Bayesian shrinkage estimator of the
observed-to-expected ratio, i.e., standardized rate, of HD among
patients at 95th percentile of PPD upon admission (‘‘end-of-life’’
HD treatment intensity) [16]. (See Figure S1. Standardized
[observed-to-expected] hemodialysis use for patients at high
probability of dying upon admission, by hospital, Pennsylvania
2001–2007.)
Statistical analyses
We first descriptively summarized the characteristics of admis-
sions in which patients received acute HD and compared them to
admissions in which patients did not receive acute HD by
employing chi-squared and t-tests. Using multivariable logistic
regression with a random effect for hospital, we calculated a
propensity score to receive acute HD based on patient- and
hospital-level covariates for every admission, stratified by age (less
Figure 1. Sample selection process. PPD - predicted probability of
death in-hospital, calculated from key clinical findings at admission; tx -
transplant; CKD - chronic kidney disease; ESRD - end-stage renal disease.
doi:10.1371/journal.pone.0105083.g001
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than 65 years old and 65 years or older). We made the decision to
stratify after a graphical analysis showed that the proportion of
admissions with acute HD peaked at age 65 and declined
thereafter.
On the basis of these propensity scores, we matched admissions
with acute HD to those without acute HD in a ratio of 1:5. If a
patient had more than one admission, we used only the first
admission, even if acute HD was not given in the first admission
but was given in a subsequent admission. The rationale for this
was to avoid bias, as a patient who underwent acute HD on a 2nd,
3rd, or subsequent admission and then died would seem to have a
shorter survival if there was ‘‘resetting of the survival clock,’’ so to
speak, to the time of that 2nd, 3rd, or subsequent admission. In
order to improve the closeness of the matches, we employed
matching with replacement, meaning that a non-HD admission
could be re-used for matching with an HD admission. To gauge
the effectiveness of matching, we used inverse probability
treatment weighting to check the covariate balance between the
acute HD and non-acute HD groups after propensity score
matching. This method allowed us to compare pre- and post-
matching samples more accurately since it maintained the original
sample size. (See Figure S2. Covariate balance before and after
inverse probability treatment weighting by propensity score.)
We plotted Kaplan-Meier survival curves of time to death, up to
one year from admission, for admissions with and without acute
HD. We then used Cox proportional hazards models to assess the
effect of acute HD on survival, with covariate adjustment.
Covariates included only patient-level variables, as hospital-level
variables were not significantly associated with survival. To reduce
indication (severity) bias, we calculated hazards of dying among
admissions with and without acute HD, matched for propensity to
receive acute HD, with covariate adjustment. We accounted for
dependence between patients within a hospital by using the
Huber-White sandwich estimator for standard errors. We
performed all analyses with Stata version 11 (StataCorp, College
Station, TX).
Sensitivity analyses
Along with our main analyses, we performed 3 sensitivity
analyses. The first only involved the calculation of propensity
scores. Due to the possibility that our sample selection process
might have incorrectly classified some HD given to ESRD patients
as acute HD, we dropped all patients with Medicare, given that
ESRD is a Medicare-qualifying condition, as well as all patients 65
years or older, given that most of them have Medicare, and again
ran the multivariable logistic regression models.
The next two sensitivity analyses involved both the calculation
of propensity scores and the survival modeling. One used the
sample selection process depicted in Figure 1 but then further
limited the sample to only admissions that included a stay in the
intensive care unit (ICU). We then conducted the same statistical
procedures as in the main analysis.
The final sensitivity analysis used the sample selection process
depicted in Figure 1 but did not exclude admissions for which the
MediQual PPD was not calculated. Instead of using the MediQual
PPD as the main risk adjustor, we used the Charlson Comorbidity
Index [17,18]. Once again, we then carried out the same statistical
procedures as in the main analysis.
Ethics statement
We conducted this research under a data use agreement with
PHC4, which acted as an honest broker to merge hospital
discharge data with PA Department of Health death records. The
University of Pittsburgh Institutional Review Board reviewed and
approved the study, which met US federal criteria for exemption
from written informed consent because data were not connected to
any patient identifiers.
Results
The characteristics of the full sample by acute HD status are
detailed in Table 1. Patients who received acute HD differed
significantly from those who did not in age, sex, race, and
insurance status. Men (P,0.001), black patients (P,0.001), and
insured patients (P,0.001) were all more likely to receive acute
HD. The most common principal diagnoses among those who
received acute HD were acute and unspecified renal failure;
septicemia; non-hypertensive congestive heart failure; respiratory
failure, insufficiency, or arrest; and diabetes mellitus with
complications. As would be expected, acute HD patients were
sicker, as reflected in their higher PPD on admission (P,0.001)
and higher mortality at every time point (P,0.001 for all).
As shown in Table 2, in multivariable logistic regression, age,
sex, race, and PPD were independently associated with receipt of
acute HD. For patients less than 65 years old, increasing age
predicted higher odds of receiving acute HD (P= 0.001); for
patients 65 years or older, increasing age predicted lower odds of
receiving acute HD (P,0.001). In both age groups, male and
black patients were more likely to receive acute HD (P,0.001 for
each). In the under-65 age group, being uninsured was associated
with lower odds of receiving acute HD (P,0.001). In both age
groups, admission to a hospital with a larger bed count (P,0.001
in under-65, P = 0.005 in 65 and older, data not shown) and
higher standardized rate of HD among patients at a high
probability of dying upon admission were associated with receipt
of acute HD (P,0.001 for both age groups, data not shown).
The characteristics of the matched sample by acute HD status
are displayed in Table 1. Of the 6113 patients who received acute
HD in the time period covered by the study, only 3483 did so in
their first admission and were therefore eligible for matching. After
matching, there was no longer a significant difference between the
groups in sex (P= 0.615). A significant difference persisted for age
measured continuously (P = 0.004), but in the matched sample the
patients who received acute HD actually had a lower mean age, as
opposed to in the full sample, in which they had a higher mean
age. Significant differences also persisted for race (P,0.001),
insurance status (P,0.001), and PPD on admission (P= 0.002), but
as Figure S2 in the supplemental digital content demonstrates,
these differences were very much attenuated in the matched
sample. Patients who did and did not receive acute HD continued
to differ significantly in mortality at every time point (P,0.001 for
all).
Figure 2 shows Kaplan-Meier curves for patients who did and
did not receive acute HD. As would be expected based upon their
illness severity, the patients who received acute HD were more
likely to die throughout the follow-up period. In the fully adjusted
Cox model before propensity score matching, the acute HD
patients had a higher risk of death (hazard ratio [HR] 1.78, 95%
confidence interval [CI] 1.58–2.00). The survival difference
persisted essentially unchanged in the fully adjusted Cox model
after propensity score matching (HR 1.82, 95% CI 1.68–1.97;
Figure 3).
The sensitivity analysis excluding patients insured by Medicare
or 65 years or older produced odds ratios qualitatively unchanged
from those obtained from the main analysis. The sensitivity
analysis restricted to patients admitted to the ICU differed notably
from the main analysis in that, for patients younger than 65,
increasing age was not significantly associated with higher odds of
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receiving acute HD (odds ratio 1.00, 95% CI 1.00–1.01, P= 0.85).
In the fully adjusted Cox model after propensity score matching,
however, the acute HD patients still had a higher risk of death
(HR 1.77, 95% CI 1.64–1.92). In the sensitivity analysis that used
the Charlson Comorbidity Index rather than the MediQual PPD
as the means of risk adjustment, the sample size increased by
almost 50% (2,131,248 to 3,174,283) since the admissions for
which PPD was not calculated were included. In this larger
sample, the hazard ratio for death after acute HD in the fully
adjusted Cox model after propensity score matching increased
(HR 2.60, 95% CI 2.41–2.80).
Discussion
This work represents one of the first descriptions of the
epidemiology of acute HD not limited to Medicare beneficiaries
in a large US population. Receipt of acute HD varied by age, sex,
race, and insurance status, even after adjustment for patients’
underlying illness severity. Furthermore, in a comparison of
patients with similar propensity to receive acute HD and adjusted
for predicted probability of death upon admission, those who did
receive acute HD had a higher risk of death for at least one year
compared to those who did not.
Table 1. Characteristics of full and matched samples by acute hemodialysis status, Pennsylvania 2005–2007.
Full sample Matched sample
No acute HD Acute HD P No acute HD Acute HD P
Admissionsa (n) 2,124,591 6,657 17,415 3,483
Patients (n) 1,283,053 6,113 16,167 3,483
Female (%) 1,201,352 (57) 3,043 (46) ,0.001 7,856 (45) 1,555 (45) 0.615
Age (yrs) 65.0617.9 65.5615.0 0.024 65.2615.9 64.4615.5 0.004
Age (%)b ,0.001 0.026
21–49 452,764 (21) 1,034 (16) 2,982 (17) 626 (18)
50–59 321,349 (15) 1,179 (18) 2,883 (17) 625 (18)
60–69 358,797 (17) 1,439 (22) 3,863 (22) 746 (21)
70–79 454,958 (21) 1,697 (25) 4,174 (24) 851 (24)
80+ 536,723 (25) 1,308 (20) 3,513 (20) 635 (18)
Race (%)b ,0.001 ,0.001
White 1,792,633 (84) 4,899 (74) 13,065 (75) 2,463 (71)
Black 218,565 (10) 1,393 (21) 3,496 (20) 816 (23)
Hispanic 38,395 (1.8) 141 (2.1) 292 (1.7) 80 (2.3)
Asian/Pacific Islander 7,798 (0.37) 27 (0.41) 84 (0.48) 20 (0.57)
Other/unknown 67,200 (3.2) 197 (3) 478 (2.7) 104 (3)
Insurance (%)b ,0.001 ,0.001
Commercial and/or Medicare 1,688,748 (80) 4,642 (70) 12,646 (73) 2,418 (69)
Medicaid with/without Medicare 404,928 (19) 1,969 (30) 4,601 (26) 1,037 (30)
Uninsured 30,142 (1.4) 44 (0.66) 168 (0.96) 28 (0.8)
Primary diagnosis (%)
Acute and unspecified renal failure 37,021 (1.7) 1,659 (25) ,0.001 4,087 (23) 816 (23) 0.959
Septicemia (except in labor) 55,833 (2.6) 900 (14) ,0.001 2,041 (12) 460 (13) 0.014
Congestive heart failure, non-hypertensive 121,786 (5.7) 547 (8.2) ,0.001 1,204 (6.9) 234 (6.7) 0.678
Respiratory failure, insufficiency, or arrest 33,132 (1.6) 328 (4.9) ,0.001 820 (4.7) 173 (5) 0.513
Diabetes mellitus with complications 40,435 (1.9) 323 (4.9) ,0.001 912 (5.2) 176 (5.1) 0.656
Predicted probability of death upon admissionc 0.03160.084 0.1460.2 ,0.001 0.1160.21 0.1360.19 0.002
Mortality (%)
During admission 50,478 (2.4) 1,258 (19) ,0.001 1,480 (8.5) 589 (17) ,0.001
By 90 d post-admit date 194,257 (9.1) 2,309 (35) ,0.001 3,047 (17) 1,059 (30) ,0.001
By 1 yr post-admit date 271,519 (13) 2,837 (43) ,0.001 3,793 (22) 1,315 (38) ,0.001
By 90 d post-admit date, conditional on surviving to discharge 143,873 (6.9) 1,061 (20) ,0.001 1,571 (9.9) 474 (16) ,0.001
By 1 yr post-admit date, conditional on surviving to discharge 221,041 (11) 1,579 (29) ,0.001 2,313 (15) 726 (25) ,0.001
Continuous variables expressed as mean 6 standard deviation; categorical variables expressed as n (%).
T-tests used for continuous variables; chi-squared tests used for categorical variables.
aAll means and proportions are based on admissions, not individual patients.
bDue to rounding, percentages may not add up to 100.
cBased upon proprietary MediQual mortality model using key clinical findings abstracted from the chart during the first 48 hours of admission.
doi:10.1371/journal.pone.0105083.t001
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Our findings that being male or black are independent
predictors of receipt of acute HD are consistent with previous
findings that these groups are more likely to receive other intensive
interventions such as mechanical ventilation [19–21], pulmonary
artery catheters [19,20], and cardiopulmonary resuscitation [22].
Other authors have also previously reported a higher rate of renal
replacement therapy among critically ill men [19]. Similarly, our
finding that the uninsured are much less likely than those with any
type of insurance to receive acute HD is in line with a recent
report by Lyon and colleagues, who, also working with the PHC4
data, noted that uninsured patients less than 65 years old had a
significantly lower probability of receiving acute HD, tracheosto-
mies, and central venous catheters [23]. It should be noted,
however, that Lyon’s strategy for differentiating acute from
chronic HD relied on older ICD-9-CM codes that didn’t allow
for separation of CKD and ESRD [24]. As such, their strategy
may have unnecessarily eliminated from acute HD analyses some
CKD patients whose HD was in fact acute. At first glance, after
seeing this kind of disparity between the insured and uninsured,
one might attribute it to healthcare providers’ reluctance to offer
expensive therapies to patients who are unlikely to ever be able to
pay for them. As Lyon pointed out, though, the disparity could
Table 2. Independent predictors of receipt of acute hemodialysis, Pennsylvania 2005–2007.a
Age,65 Age$65
Adjusted
odds ratio
95% confidence
interval
Adjusted
odds ratio
95% confidence
interval
Age (per year) 1.01 1.00–1.01 0.95 0.94–0.95
Female 0.79 0.73–0.86 0.85 0.79–0.91
Black 1.37 1.24–1.52 1.54 1.37–1.73
Uninsured (vs. Medicare/commercial) 0.49 0.35–0.68 0.58 0.27–1.25
Uninsured (vs. Medicaid 6 Medicare) 0.35 0.25–0.48 0.58 0.27–1.27
Primary diagnoses (top 5 by prevalence over all ages)
Acute and unspecified renal failure 57.9 51.4–65.2 31.3 28.2–34.6
Septicemia (except in labor) 10.8 9.35–12.6 5.57 4.89–6.36
Congestive heart failure, non-hypertensive 6.30 5.31–7.49 3.80 3.34–4.33
Respiratory failure, insufficiency, or arrest 5.55 4.54–6.77 3.12 2.63–3.71
Diabetes mellitus with complications 7.19 6.06–8.54 8.22 6.85–9.86
Predicted probability of inpatient death (per 1%
increase)
49.6 40.0–61.4 39.0 32.9–46.3
aBased on the full sample.
doi:10.1371/journal.pone.0105083.t002
Figure 2. Unadjusted survival among patients with and
without acute hemodialysis, Pennsylvania 2005–2007. Kaplan-
Meier survival curves for patients who did and did not receive acute
hemodialysis, with 95% confidence intervals.
doi:10.1371/journal.pone.0105083.g002
Figure 3. Adjusted survival among propensity-score matched
patients with and without acute hemodialysis, Pennsylvania
2005–2007. Cox-adjusted survival curves with covariate adjustment
for patients who did and did not receive acute hemodialysis after
matching on propensity to receive acute hemodialysis. Variables
included in covariate risk adjustment included age; female sex; black
race; insurance with Medicare or private insurance vs. no insurance;
insurance with Medicaid and/or Medicare vs. no insurance; MediQual
predicted probability of death; and the top 25 Clinical Classification
Software admission diagnoses for people who received acute
hemodialysis, with the exception of hypertension with complications
and secondary hypertension (#6) and peripheral and visceral athero-
sclerosis (#25), which were dropped in the model selection phase.
doi:10.1371/journal.pone.0105083.g003
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result more from choices by the uninsured patients and their
surrogates than from healthcare providers’ decisions—unconscious
or otherwise—to forego these interventions in the uninsured. The
reasons underlying the observed disparity merit further investiga-
tion, perhaps using survey-based or qualitative methods.
Perhaps the most striking finding from our study is the increased
mortality risk for patients who received acute HD, even after
robust risk-adjustment, including propensity score matching. Even
after we limited the sample to the sickest patients, those admitted
to the ICU, this increased mortality risk persisted. This finding
runs counter to the commonly accepted notion that acute HD
decreases mortality for those in whom it is initiated. Certainly,
despite our best efforts to match by propensity to receive acute HD
patients who did and did not receive it, the possibility of
unmeasured confounding by illness severity remains. Though a
principal diagnosis of AKI was a covariate in our propensity
scoring and survival models, we could not match patients on
severity of AKI (e.g., by serum BUN or creatinine or urine output),
as our dataset did not include that information.
However, we also cannot rule out the possibility that acute HD
is deleterious to patient survival. Elseviers and colleagues reported
similar results from a nonrandomized prospective study of 1,303
patients in 9 ICUs [25]. They found that differences in illness
severity did not account for the higher in-hospital mortality
observed in patients who received acute HD. Intriguingly, they
also noted wide variations between ICUs in initiation of acute HD,
underscoring the general lack of consensus in nephrology and
critical care about the relative indications for this therapy. In our
study, we attempted to account for between-institution variations
by including each hospital’s standardized rate of HD among
patients at a high probability of dying in our propensity score
calculation and appropriately adjusting Cox model standard errors
for clustering of patients within hospitals.
Two even more recent studies, though they did not find higher
mortality with acute HD, did find lack of survival benefit. For
Clec’h and colleagues, this lack of benefit was in patients who
received acute HD versus those who did not after matching on
propensity to receive acute HD using detailed clinical information
[26]. For Wilson and colleagues, this lack of benefit was in patients
who developed severe AKI on days other than Sundays compared
to patients who developed severe AKI on Sundays, despite lower
frequency of acute HD initiation on Sundays [27]. Moreover,
Wilson and colleagues, in their most recent study, observed an
association between dialysis for AKI and increased survival when
dialysis was initiated in patients with higher serum creatinine but
not when it was initiated in patients with lower serum creatinine.
In fact, in patients with lower serum creatinine, initiation of
dialysis for AKI was associated with increased mortality [28].
Though the reasons that acute HD might exert either no effect or
a negative effect on patient survival are far from clear and merit
further research, the known risks of HD—episodic hypotension, an
indwelling catheter, immune and coagulation disturbances,
changes in medication clearance, to name a few—all might play
a role.
Our study has several strengths that should be noted. Our
sample includes over 2 million observations from a dataset that
captured admissions of all adults in almost every hospital in a
populous US state, not just Medicare beneficiaries or hospitals
within a particular commercial or government healthcare system.
Our analyses benefitted from the precise risk adjustment of the
MediQual model for predicted probability of death. Furthermore,
by restricting our sample to admissions from the last quarter of
2005 onwards, we were able to take advantage of updated ICD-9-
CM codes that allow for separation of CKD and ESRD. As such,
we can have reasonable confidence in our ability to differentiate
between acute and chronic HD using administrative data.
This study is not without weaknesses, however. Though we
carefully crafted our strategy to exclude ESRD patients from the
sample and backed it up with a sensitivity analysis, without
medical records we are unable to fully validate the strategy.
Despite adjusting for a wide variety of covariates in our models
and propensity-score matching patients who received acute HD
with patients who did not, as well as replicating our main results
with a sensitivity analysis limited to patients sick enough to be
admitted to the ICU, there is still likely to be some degree of
unmeasured confounding contributing to the survival difference
between the groups. In the most extreme case, if the only patients
dialyzed were those who would have definitely died from their
illness, then acute HD had to confer a survival benefit, as some
patients did survive. While we cannot exclude this possibility using
our dataset, we mitigated it to the fullest extent that our dataset
would allow. Finally, in order to use the precise risk adjustment of
the MediQual model, we excluded all those admissions for which
PHC4 did not require calculation of predicted probability of
death. Our sample must therefore be considered nonrandom. In
fact one of our sensitivity analyses did demonstrate that the
inclusion of all admissions in our sample would have altered the
results. But the most important finding, the hazard ratio for death
in patients who received acute HD versus those who did not,
actually became larger in this case.
Taken in the context of previous research, our findings
regarding predictors of acute HD suggest factors other than
clinical indication at play in determining who receives this therapy;
our findings regarding survival after acute HD raise questions
about its presumed benefits. Given the extraordinary costs of
intensive interventions such as acute HD in the US, and the ever-
expanding population of patients who might become ill enough to
be viewed as candidates for it, healthcare providers and policy-
makers alike must carefully consider why exactly patients receive
the therapies they do and whether those reasons impact eventual
outcomes.
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Figure S1 Standardized (observed-to-expected) hemo-
dialysis use for patients at high probability of dying
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